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Background: We prospectively studied the impact of an adherence counselor on the outcome of 
patients failing antiretroviral therapy because of nonadherence. Methods: Forty-six patients, 
identified as chronically nonadherent were enrolled. Individual attention was provided using the 
information, motivation and behavioral methodology. HIV RNA (viral load, in copies/mL), CD4 
count (in cells/[mm.sup.3]), and body weight before and after the adherence counselor were 
measured. Qualitative outcome and patient satisfaction were assessed by deidentified third-party 
interviews. Results: Over half completed at least 1 year; only 8 patients were lost to follow-up. 
Mean CD4 counts increased significantly (P < .05) for completers at 6 and 12 months. Viral 
loads decreased between baseline and 6 months. Most clients reported subjective benefit from 
working with the adherence counselor. Conclusion: Although few clients showed complete 
virologic suppression, the value of an adherence counselor was validated. Longer term adherence 
programs should be evaluated.  
Keywords: adherence; failure of medical management; compliance; counseling; HIV outcomes  
Once the decision to start therapy has been determined, adherence to antiretroviral therapy is 
essential for the clinical management of HIV infection. Yet multiple studies have revealed poor 
adherence to antiretroviral regimens resulting in failure to suppress HIVRNA values, the 
emergence of drug-resistant strains, and more rapid progression of illness to clinical and 
surrogate end points. (1-8) This problem is not new. Poor adherence to medication has been 
recognized as problematic since the writings of Hippocrates (460-377 BC) who advised that 
physicians should "be alert to the faults of patients which often make them lie about the taking of 
medicines prescribed." (9) Consequently, increased attention has been paid to the problem of 
adherence and methods for promoting good adherence in recent HIV literature.  
Adherence to highly active antiretroviral therapy (HAART) is a challenge for even the motivated 
client. Multiple drugs, complex dosing schedules, dietary restrictions, and significant short-term 
and long-term side effects are frequent complaints. Clients themselves have comorbidities that 
impact adherence: mental illness, poor relationships with providers, transportation and access 
issues, poverty, substance abuse, social environment and living conditions, personal belief 
systems, and concomitant physical illnesses. Social prejudices against HIV/AIDS may create 
further obstacles, as patients may not want colleagues, friends, or family to know about the 
illness, thereby making it hard to maintain complex medication regimens. Poor relationships with 
providers result in less than optimal clinical results: more than any other factor in urban HIV 
clinics, missed clinic appointments correlate with unsuccessful treatment. (10)  
Roberts (11) identified 5 main barriers to adherence in a series of client interviews: forgetfulness, 
social and physical environment, antiretroviral regimen complexity, medication side effects, and 
inadequate patient knowledge. She concluded that patients might overcome some of these 
barriers by receiving better education about the nature of HIV/AIDS and the need for medication 
adherence, professional and lay support, and mechanical reminders such as alarm clocks and 
medisets. These results also indicate the need for additional research into how psychosocial 
factors and personal beliefs impact adherence in HIV/AIDS. (12-17)  
This study utilized the information, motivation, and building skills methodology (IMB) (18) and 
was designed to assess whether the introduction of an adherence counselor has a positive impact 
on adherence characteristics and clinical outcomes in a cohort of patients with a history of poor 
adherence to medical treatment. Others have shown that success may be achieved in such 
populations by assuring readiness and finding the right provider. (19) In addition to measuring 
quantitative end points, we assessed qualitative information from clients about the effectiveness 
of the adherence counselor to determine whether this type of program will benefit other clients, 
providers, and support service agencies. Qualitative methods help to demonstrate the humanistic 
perspective and are beneficial in answering psychosocial questions about how individual patients 
cope with the demands of taking antiretroviral medications and living with HIV infection. At 
least 95% adherence to antiretroviral therapy is necessary to limit the risk of resistance to 
medications. Recognizing this, the investigators undertook this study to determine the impact of 
individualized holistic attention, in the form of an adherence counseling intervention, on the 
health and outlook of clients identified as recalcitrant by the study investigators.  
Methods  
Study Overview  
The adherence counselor position was created to provide individual attention to adherence issues 
for HIV-positive clients attending the immunology (HIV) clinic at the Stamford Hospital, a 300-
bed community teaching hospital in southwestern Connecticut. The clinic serves approximately 
400 clients; at any given time about 200 are consistently and regularly using clinical services. Of 
the clients using the clinic, 50% are African American and 27% are Hispanic or Latino. Greater 
than 35% are drug users or former drug users, and 6% are homeless. The clinic serves a 
predominantly indigent clientele. Requirements for the adherence counselor position included 
excellent communication skills, compassion, spirituality, flexibility in scheduling, awareness of 
the community, and an in-depth knowledge of HIV and its medical management. Funding for the 
position was obtained from federal Ryan White Title II care funds provided through the State of 
Connecticut Department of Public Health to Stamford CARES, a not-for-profit HIV service 
organization.  
From March 2000 to February 2001, 46 HIV-infected individuals older than 21 years were 
consecutively identified by the infectious diseases physicians and/or the HIV nurse practitioner 
as having long-standing difficulty adhering to antiretroviral therapy. Patients had been diagnosed 
as HIV infected from 1985 through 1999, with a mean infection duration of 6.8 years. Adherence 
to HIV management is difficult to measure, (20) but for this study, nonadherence was defined by 
persistently high HIV viral load values (Roche Amplicor HIV RNA polymerase chain reaction 
values of more than 10 000 copies/mL) despite prescribed antiretroviral treatment, frequently 
occurring together with poor clinic attendance and self-reported poor adherence. These clients 
were referred to the adherence counselor. Table 1 details the plan for implementation of 
adherence counseling.  
 
 
On referral, the adherence counselor, who was also a registered nurse and family therapist, 
performed a comprehensive medical and psychosocial assessment of each client for his or her 
ability to adhere to therapy. The assessment occurred in a location identified by the client as 
comfortable for him or her. The adherence counselor provided intense, full-time, one-on-one 
education, nursing support, and comprehensive adherence resources (eg, directly observed 
therapy, phone calls, pharmacy pickups, pillboxes) tailored to the individual needs of the client 
and as agreed to by the client. A client-centered plan was developed based on the individual 
client's strengths and weaknesses, level of understanding, psychosocial situation, and motivation. 
Necessary referrals were made to maximize support. Weekly progress and achieved adherence 
goals were recorded in a client record. Pill counts as well as self-report were used to determine 
adherence to regimens. Medical aspects of the client's care were not purposefully manipulated.  
The IMB (18) methodology was used to structure care plans and encourage behavior change. 
This model incorporates provision of information and intense education about the disease and 
medication used for treatment and includes a motivational component to reinforce the 
importance of adherence and to offer support and encouragement while providing follow-up 
immediately after the client starts taking medication or changes medication. The client is then 
helped to build behavioral self-care skills such as accurately filling a pillbox, reordering 
medication from the pharmacy, and identifying cues during activities of living to serve as 
reminders of scheduled doses. Vital to the care plan were interventions including assessment of 
adherence barriers, reinforcement of importance of adherence, and support encouragement at 
follow-up visits.  
Quantitative measurements were performed 6 months before baseline (obtained retrospectively), 
at baseline (first contact with the adherence counselor), and then prospectively at 6 and 12 
months after the introduction of the adherence counselor. CD4 counts, HIV RNA (viral load) 
values, and patient weights were recorded using codes for each client. Treatment regimens were 
selected by the infectious disease clinicians providing care for all patients, using contemporary 
AIDS treatment guidelines. (1)  
A one-on-one confidential client interview was conducted after the study was completed at 12 
months. Clients discussed their experiences and evaluated the benefit of the Adherence 
Counselor Program. To prevent bias, a trained interviewer who was previously unknown to the 
client and was never involved in the client's care conducted the interviews. The interviewer 
followed a scripted format of questions to provide consistency. The questions focused on views 
and feelings of living with HIV/AIDS before the intervention, working with the adherence 
counselor, medication taking, the quality and success of the treatment plan, the value of the 
program, the least helpful components of the program, and advice the client would offer other 
HIV-positive clients and practitioners working with HIV-positive clients. All clients, completer 
and noncompleters, who were reachable by phone were invited to participate in the confidential 
interview. Interviews were held either in a room within the hospital complex or at the client's 
home, according to the client's preference. Interviewee comments were deidentified by the 
interviewer before transmission to the investigators. Each client who completed the interview 
process was given $25.00 for his or her time. Interviews were audiotaped, transcribed verbatim, 
and reviewed for common themes. Clients were given the opportunity to review the transcribed 
data to ensure accuracy in transcription. Informed consent was obtained before enrollment 
pursuant to institutional review board approval of the study.  
Data Analysis  
Forty-six nonadherent HIV-infected adults were entered in the adherence program study. 
Twenty-eight patients (61%) completed 1-year follow-up in the program, 8 were lost to follow-
up or refused follow-up, and 5 died during the course of the year. Four patients elected no 
antiviral therapy, and 1 patient was eliminated because of a lack of a complete set of data before 
the start of the study. Mean values of serial CD4, HIV RNA, and weight for all 28 completers 
were compared over time; statistical conclusions were drawn by analysis of variance with a 
priori contrasts. Individual clients were further evaluated with respect to changes in viral load 
using the following definitions: patients were arbitrarily categorized as likely to be either 
adherent (viral load less than 400 copies/ mL), moderately adherent (viral load of 400-10 000 
copies/ mL), or nonadherent (viral load greater than 10 000 copies/mL). Changes in individual 
CD4 counts over time were also categorized as likely to be either nonadherent (increase relative 
to baseline less than 25%) or adherent (increase greater than 25%). Changes in these parameters 
were evaluated by the Wilcoxon signed rank test.  
Results  
As Treated  
After the introduction of the adherence counselor, mean CD4 counts increased significantly (P < 
.05) from baseline counts (mean [+ or -] 1 SD; 244 [+ or -]240 cells/[mm.sup.3]) to 6 month (290 
[+ or -]268 cells/[mm.sup.3]) and 12 month counts (306 [+ or -] 272 cells/[mm.sup.3])(Figure 
1A). Viral load values decreased significantly only between baseline and 6-month assessments 
(147 880 [+ or -] 200 423 vs 61 190 [+ or -] 137 296 copies/ mL)(Figure 1B). The percentage of 
patients with at least moderate adherence based on viral load increased significantly (P < .05) 
between baseline and 6 months (7% vs 57%) and between baseline and 12 months (7% vs 43%) 
(Table 2). Patients with at least moderate adherence were more likely than nonadherent patients 
to experience an increase of at least 25% in CD4 counts at 6 months (68% vs 25%). No 
statistically significant change in patient weight was appreciated, despite a trend to increase 
(Figure 1C). Viral load values, more than even CD4 counts, demonstrated wide variability 
(range, <50-750 000 copies/mL), resulting in high standard deviation values (Figure 2).  
Intent to Treat  
Although mean CD4 counts rose (Figure 3), only 61% of the 46 patients who entered the 
program completed a full year of follow-up, and only one quarter (26%) had become at least 
moderately adherent by the end of 1 year. Based on more stringent criteria, only 4 (8.7%) of 46 
patients had become fully adherent by all 3 measures: self-report, investigators' consensus, and 
viral load values less than 400 copies/mL. Eight patients were lost to follow-up or had moved, 5 
patients died, 4 patients elected to discontinue HAART, and 1 patient was eliminated because of 
an incomplete data set before study entry.  
Qualitative Data Analysis  
Qualitative data from 10 patient interviews were transcribed and separated into 4 types of data: 
perceptions before the intervention, perceptions at the beginning of the intervention, perceptions 
during the program, and reflective advice from the patient. The authors and the interviewer 
identified themes for each of these periods. In the first stage, feelings of denial and isolation were 
a common theme. Denial is a way of protecting oneself from the shock of the disclosure of a 
terminal illness. For some patients, denial is needed until death. For many patients, denial 
provides the needed time to understand the diagnosis and organize more lasting coping 
mechanisms. Most participants described the time period before this intervention, which ranged 
from a few years to more than a decade, as a time of denial, fear, depression, and shock. Some 
examples of comments to support this theme of denial were "I didn't want to be around nobody; I 
was all by myself"; " I didn't understand it; I tried to hide myself"; and "I was ashamed and 
embarrassed." Some clients recognized the denial and told the interviewer "Big denial"; "It 
wasn't reality"; "It was something they were just saying"; "I wasn't facing that I had it"; and "It 
was hectic, shocking; I was in denial for a long time with it." In our study group, we saw 
evidence of clients' using illicit street drugs to avoid dealing with the HIV diagnosis. Excerpts 
from interviews include the following: "I was still running the streets/drugging, because I wanted 
to forget" and "I was into drugs, cocaine, and drinking."  
Difficulty with medications was another theme during the interval before the intervention. All of 
the subjects made statements regarding various aspects of medication taking that impeded the 
ability to adhere to regimens, including references to side effects, number of pills, and pill 
fatigue. In fact, one client stated, "I just hate taking medication." Other examples of statements 
relating to this issue included side effects and the amount of pills: "Pills made me sick, I hurt, felt 
better not taking them"; "Made me nauseous, it affected my attitude, felt funny and woozy"; 
"Never took my meds before [the adherence counselor], I couldn't--there were too many"; and "I 
was taking like 16 drugs a day, and I was tired of it."  
 
 
In the beginning of the intervention, once the patient agreed to work with the adherence 
counselor, an individualized plan was prepared (see Methods above). At first, some of the 
patients resisted the efforts of the counselor. Such patients are often perceived as difficult and 
ungrateful and frequently provoke undesired reactions from those who try to care for them. One 
subject commented on the value of persistence on behalf of the adherence counselor: "At first I 
didn't want to work with nobody because I didn't feel like I needed to." Other comments included 
the following: "When she was calling me, I kept flushing her off, but she kept calling, which was 
cool"; "At first I didn't want to work with her, because I didn't want nobody to get into my 
business, then I came around"; and even "She gave me the pillboxes, showed me how to lay 
them out, but when I got home, I would throw them in the garbage."  
The HIV education portion of the program was well received. Excerpts to verify this finding 
include the following: "I started learning about it and taking it more seriously"; "The more I 
learn, the better it helps me"; "I got a book to see what each pill means, a pamphlet to read up on 
it, a card to write it down, so I didn't forget"; and "I realized, no more fooling around." A benefit 
of working one-on-one with a caring counselor was the improvement in communication. Even 
though the counselor asked a lot of questions, clients felt this questioning was helpful because 
they started communicating with someone about their disease.  
 
 
During the study, subjects revealed 3 things that challenged them in adhering to the medication 
program. One issue was the medications: the antiretroviral pills, the amount, the need to eat or 
not to eat with medications, the size of the pills, and the side effects. Another challenge was peer 
pressure to do illicit drugs and drink alcohol. A third challenge was apathy and depression, 
mentioned by almost every interviewee. One participant stated, "Sometimes I think I am going to 
die, too much stuff in my head."  
Every participant in this study made positive statements about the qualities of the Adherence 
Counselor Program. The words strength and power were noted throughout this part of the 
interview. Patients felt the program helped them improve their situation. Spirituality was also a 
common thread; most clients expressed a belief that God would continue to help them cope with 
life. Having someone professional and confidential to share information with gave the clients a 
better outlook on the future. Many patients stressed the value of confidentiality. The adherence 
counselor's ability to be a good listener and to inspire was important to the interviewees, helping 
them improve their outlook on the future and of their own abilities.  
Cost  
Program expenses were primarily attributable to salary and fringe benefits for the adherence 
counselor. These expenses totaled approximately $61 350. Travel, telephone, and pager expenses 
were approximately $1500. Adherence tools were mostly provided free by separately funded 
state or local programs and pharmaceutical companies. Out-of-pocket expense for these items 
was about $400. Meetings, staff education, and supplies expenses were budgeted at $1200. There 
were no significant additional space or secretarial expenses. The total annual program cost, $64 
450, benefited more than the 28 clients who completed this study. It included more than 1000 
client contacts (including 300 patient visits in the immunology clinic) and at least monthly 
contact with all the study clients, for an average cost per client contact of $48. Additional testing 
and medical care attributable to better adherence was not factored into these computations.  
Discussion  
Poor adherence to HAART is common. Patients may miss up to one third of all medication 
doses, and up to one fifth of the patients never fill their initial prescriptions. (10) Studies have 
shown that for optimal viral suppression, patients must take more than 95% of prescribed doses. 
Lesser degrees of adherence are associated with higher rates of virologic failure, immunologic 
deterioration, and progression of clinical disease.  
 
 
Multiple patient-focused interventions to increase adherence have been reported elsewhere to be 
of value and were incorporated into our program. (21-27) These interventions included providing 
financial counseling and support, providing free medication, streamlining medication schedules 
to once or twice daily, and coordinating medication taking into the patient's daily living 
schedule. The need to establish trust, provide spiritual support, utilize peer groups, provide 
access to nonphysician caregivers, link viral load and CD4 counts to therapy, monitor and 
aggressively treat adverse events, and share results with patients are all acknowledged and were 
utilized by this program. Strategies also involved intense education regarding the purpose of the 
medications, anticipated outcomes, importance of a medication schedule, and reportable side 
effects. Directly observed therapy, medication boxes, handouts with times and medications, and 
cue cards were used for each individual patient, as appropriate. Positive feedback and sharing 
laboratory results with graphic displays and flowcharts also motivated patients' continued 
adherence. It is crucial that patients and clinicians work together to achieve successful adherence 
to medication therapy. (19,28)  
Attempting to incorporate multiple adherence interventions into the context of a busy practice or 
clinic may not be possible. A poorly motivated client becomes lost in this scenario; therefore, we 
prospectively designed our study to add a dedicated adherence counselor to the care of a 
historically nonadherent group. Our concept was to provide customized, individual attention to 
each of the 46 clients enrolled in this program. Such attention was not limited to clinic time but 
was completely flexible to fit in with the client's availability and perceived individual needs. This 
program benefited all the clients using the immunology clinic as well as the 28 clients 
participating in the study, averaging $48 per client contact and $64 450 annually.  
 
 
After intense adherence management for 1 year, we were able to recruit about one quarter of 
these clients into improving their behavior into what we judged at least moderately adherent, and 
8.6% actually achieved full virologic suppression. Perhaps also noteworthy, 60% actually 
became compliant enough to allow serologic follow-up every 3 to 6 months. Because we did not 
assess for preexisting drug resistance, it is possible that a larger percentage would have become 
virologically suppressed if treatment had been customized according to viral genotype or 
phenotype. In our qualitative evaluation, many clients clearly expressed that their improved 
performance was attributable to the adherence counselor.  
This study illustrates the value that a dedicated adherence counselor may have in promoting 
clients' adherence to antiretroviral therapy and, in the very least, to maintain connection to their 
health care. Only 8, or 17%, of the 46 clients we identified as recalcitrant were lost to follow-up; 
61% completed the program. Although there may be features unique to our study site and to our 
adherence counselor, there are some clients who will always refuse treatment options and 
support. There is certainly value to dedicated adherence counseling time in HIV management, 
which may help reduce the risk of loss to follow-up and improve patient monitoring. Success in 
such programs will undoubtedly promote better clinical outcomes and should retard the 
development of antiretroviral drug resistance.  
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Table 1. Plan for Implementation of Adherence Counseling 
  
1.   Medical provider refers client to adherence counselor. 
2.   On receipt of referral, schedule an appropriate time to do initial 
     assessment (medical and psychosocial). Assessment is 
     done at the client's home, the hospital, by phone contact, or 
     any appropriate site where the client is comfortable. 
3.   Assess clients' strengths and weaknesses to enhance adherence, 
     level of understanding of the disease and the need for medication, 
     physical, and psychosocial situation that may influence 
     adherence, skills to effectively master adherent practices, and 
     client motivation. 
4.   Develop a client-centered care plan. 
5.   Provide adherence tools (eg, phone calls, pillboxes, beepers, 
     picture charts, written instructions, rewards or incentives, 
     home visits). 
6.   Offer daily contact with client at onset (telephone, visits) to 
     include directly observed therapy, if appropriate, and taper as 
     tolerated according to adherence achieved. 
7.   Assist client with obtaining necessary support for maximizing 
     adherence to medication and/or treatment (eg, referral to 
     Ryan White case manager, pharmacist, drug counseling, medical 
     and social programs, community resources, pastor, family, 
     friends, peer support groups). 
8.   Track progress of meeting medication adherence goal in client 
     record at least weekly. 
9.   Meet weekly with care team, including HIV nurse practitioner, 
     physicians, Ryan White case manager. 
  
Table 2. Ranges of Viral Load and CD-4 Count Values in 
Patients Who Completed 1 Year of Follow-up With the 
Adherence Counselor * 
  
HIV RNA, copies/mL 
  
Range            Baseline   6 mo      12 mo 
  
0-10 000          2 (7)     16 (57)   12 (43) 
10 000-100 000   14 (50)    8 (29)    10 (36) 
>100 000         12 (43)    4 (14)    6 (21) 
  
CD4 absolute counts, cells/[mm.sup.3] 
  
Range            Baseline   6 mo      12 mo 
  
<200             14 (50)    11 (39)   12 (43) 
201-350           6 (21)    10 (36)   9 (32) 
>350              8 (29)    7 (25)    7 (25) 
  
* Values are presented as no.(%). 
  
Figure 1 A, mean CD4 count values for the group of 28 patients 
completing 12 months of treatment. B, mean HIV RNA values 
(viral load, in copies/mL) for the group of 28 patients completing 
12 months of treatment. C, mean patient weight, in 
pounds, for the group of 28 patients completing 12 months 
of treatment. 
  
A                    Mean CD4 count 
  
6 months prior           261 
Immediately prior        244 
6 months after           290 
12 months after          306 
  
B                    Mean Viral Load 
  
6 months prior          61,011 
Immediately prior       97,175 
6 months after          61,189 
12 months after         92,789 
  
C                    Mean Weight 
  
6 months prior          154.8 
Immediately prior       155.6 
6 months after          156.3 
12 months after         157.9 
  
Note: Table made from bar graphs. 
 
